Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GMI 1687

Next Previous
Drug Profile

GMI 1687

Alternative Names: APL-108; GMI-1687

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Developer Apollomics; Crescent Biopharma
  • Class Antineoplastics; Antithrombotics; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Inflammation; Multiple myeloma; Thrombosis; Vaso-occlusive crisis

Most Recent Events

  • 16 Jun 2025 GlycoMimetics has merged with Crescent Biopharma to form Crescent Biopharma
  • 21 May 2025 Apollomics terminates its licence for uproleselan in China, Hong Kong, Macau, Taiwan
  • 31 Mar 2025 Discontinued - Phase-I for Inflammation (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top